CLINICAL DATA ACHIEVES VALIDATION OF GENETIC BIOMARKER FOR DETERMINING RISK OF CLOZAPINE INDUCED AGRANULOCYTOSIS

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that its PGxHealth division has completed the validation of a genetic marker that will help identify patients at risk for Clozapine-Induced Agranulocytosis (CIA), a potentially deadly blood disorder. This gene is located in the HLA complex, an area that, as has been previously reported, is associated with CIA.
Genetic Engineering News